Related Experiment Video

Updated: Jun 13, 2026

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
06:43

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib

Published on: April 3, 2026

New medical strategies for midgut carcinoids

Ola Nilsson1, Yvonne Arvidsson, Viktor Johanson

  • 1Department of Pathology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Anti-Cancer Agents in Medicinal Chemistry
|April 22, 2010
PubMed

Insights

New treatments for gastrointestinal neuroendocrine tumors (NETs) are emerging. This review explores targeted therapies, including angiogenesis inhibitors and pathway modulators, to improve outcomes for metastatic NET patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Gastrointestinal neuroendocrine tumors (NETs) frequently present with metastases and hormonal symptoms.
  • Current palliative treatments include tumor reduction and somatostatin analogues, with limited chemotherapy options.
  • Neuroendocrine tumors express specific receptors crucial for growth, vascularization, and spread.

Purpose of the Study:

  • To review novel therapeutic strategies for well-differentiated gastrointestinal neuroendocrine tumors.
  • To explore emerging treatments targeting specific molecular pathways and receptors.
  • To identify potential combination therapies to enhance treatment efficacy.

Main Methods:

  • Review of clinical and experimental studies on novel NET treatments.
  • Analysis of targeted therapies including angiogenesis inhibitors and tyrosine kinase inhibitors.
  • Exploration of interference with cellular pathways like mTOR, PI3K, RAS/RAF, and Notch.

Main Results:

  • Targeted therapies show promise, including inhibition of angiogenesis and growth factor receptors.
  • Interference with specific cellular pathways (mTOR, PI3K, RAS/RAF, Notch) represents a potential strategy.
  • Inhibition of proteasome and histone deacetylation are also explored avenues.
  • Combination therapies, including targeted agents with chemotherapy or radionuclide therapy, may improve outcomes.

Conclusions:

  • Targeted therapies offer new hope for managing metastatic gastrointestinal neuroendocrine tumors.
  • Interfering with specific molecular pathways and receptor signaling is a key focus for future treatments.
  • Combination strategies hold potential for enhancing the efficacy of existing and novel therapeutic approaches.

Related Concept Videos

Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Peptic Ulcer Disease V: Surgical Management and Nursing Care01:25

Peptic Ulcer Disease V: Surgical Management and Nursing Care

Surgical management and nursing care are crucial in treating Peptic Ulcer Disease (PUD). Here is an organized and enhanced overview of the surgical interventions and the associated nursing care for PUD:
Surgical Interventions for Peptic Ulcer Disease
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...